Stock Track | Mesoblast Soars 5.22% Intraday on Acquisition of CAR-MSC Platform with Exclusive Mayo Clinic License

Stock Track

Apr 15

Mesoblast Ltd's stock surged 5.22% during intraday trading on Wednesday, following a series of announcements regarding a significant strategic acquisition.

The company acquired a startup holding an exclusive worldwide license to patented Chimeric Antigen Receptor (CAR) technology for genetically engineered mesenchymal stromal cell (MSC) products. This platform, developed at the Mayo Clinic, is designed to improve MSC targeting to inflamed tissue, thereby boosting potency in treating inflammatory diseases.

Key near-term development focuses include CAR-MSC candidates for conditions such as ulcerative colitis and Crohn's disease, with future plans for candidates engineered to target B-cell autoimmune diseases like lupus nephritis. The Mayo Clinic will also provide in-kind support and GMP manufacturing for the technology. The consideration for the acquisition was paid via the issuance of ASX ordinary shares, highlighting a strategic expansion of Mesoblast's regenerative medicine portfolio.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/news/1120433271"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1120433271\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1120433271?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-15 08:18","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1120433271","market":"us","top_or_hot":-1,"title":"Stock Track | Mesoblast Soars 5.22% Intraday on Acquisition of CAR-MSC Platform with Exclusive Mayo Clinic License","media":"Stock Track","content":"<p>Mesoblast Ltd's stock surged 5.22% during intraday trading on Wednesday, following a series of announcements regarding a significant strategic acquisition.</p><p>The company acquired a startup holding an exclusive worldwide license to patented Chimeric Antigen Receptor (CAR) technology for genetically engineered mesenchymal stromal cell (MSC) products. This platform, developed at the Mayo Clinic, is designed to improve MSC targeting to inflamed tissue, thereby boosting potency in treating inflammatory diseases.</p><p>Key near-term development focuses include CAR-MSC candidates for conditions such as ulcerative colitis and Crohn's disease, with future plans for candidates engineered to target B-cell autoimmune diseases like lupus nephritis. The Mayo Clinic will also provide in-kind support and GMP manufacturing for the technology. The consideration for the acquisition was paid via the issuance of ASX ordinary shares, highlighting a strategic expansion of Mesoblast's regenerative medicine portfolio.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Mesoblast Soars 5.22% Intraday on Acquisition of CAR-MSC Platform with Exclusive Mayo Clinic License</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Mesoblast Soars 5.22% Intraday on Acquisition of CAR-MSC Platform with Exclusive Mayo Clinic License\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-04-15 08:18</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Mesoblast Ltd's stock surged 5.22% during intraday trading on Wednesday, following a series of announcements regarding a significant strategic acquisition.</p><p>The company acquired a startup holding an exclusive worldwide license to patented Chimeric Antigen Receptor (CAR) technology for genetically engineered mesenchymal stromal cell (MSC) products. This platform, developed at the Mayo Clinic, is designed to improve MSC targeting to inflamed tissue, thereby boosting potency in treating inflammatory diseases.</p><p>Key near-term development focuses include CAR-MSC candidates for conditions such as ulcerative colitis and Crohn's disease, with future plans for candidates engineered to target B-cell autoimmune diseases like lupus nephritis. The Mayo Clinic will also provide in-kind support and GMP manufacturing for the technology. The consideration for the acquisition was paid via the issuance of ASX ordinary shares, highlighting a strategic expansion of Mesoblast's regenerative medicine portfolio.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"MSB.AU","symbol_name":"MESOBLAST LTD","start_time":0,"source_url":"","article_id":"1120433271","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1120433271","pubTimestamp":1776212319,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Mesoblast Ltd's stock surged 5.22% during intraday trading on Wednesday, following a series of announcements regarding a significant strategic acquisition.The company acquired a startup holding an...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"MSB.AU":"MESOBLAST LTD"},"translate_title":"股票追踪|Mesoblast盘中大涨5.22%收购CAR-MSC平台并拥有梅奥诊所独家授权","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MSB.AU":1},"content_text":"Mesoblast Ltd's stock surged 5.22% during intraday trading on Wednesday, following a series of announcements regarding a significant strategic acquisition.The company acquired a startup holding an exclusive worldwide license to patented Chimeric Antigen Receptor (CAR) technology for genetically engineered mesenchymal stromal cell (MSC) products. This platform, developed at the Mayo Clinic, is designed to improve MSC targeting to inflamed tissue, thereby boosting potency in treating inflammatory diseases.Key near-term development focuses include CAR-MSC candidates for conditions such as ulcerative colitis and Crohn's disease, with future plans for candidates engineered to target B-cell autoimmune diseases like lupus nephritis. The Mayo Clinic will also provide in-kind support and GMP manufacturing for the technology. The consideration for the acquisition was paid via the issuance of ASX ordinary shares, highlighting a strategic expansion of Mesoblast's regenerative medicine portfolio.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}